BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
Recs
Interesting spin-off of PPDI with nearly as much cash on its balance sheet as its market cap.The theory here is that such a small spin-off of such a large company was likely unwanted by many large investors and hence sold, creating an undervalued security. Furthermore, like is the case with many spin-offs, significant insider ownership aligns management with shareholders.The company is burning cash, so this is far from a pure asset play.David Einhorn recently reported being long FURX in his latest quarterly report. That's what initially brought this company to my attention. I have since found out a great deal of information on the company by reading Farukh Farooqi's great write-up on it here:http://seekingalpha.com/article/220842-furiex-pharma-s-cash-will-likely-run-out-before-investors-feel-secure?source=yahooDeej